REFERENCES
  1. Robert J Motzer, Bernard Escudier, Stéphane Oudard, Thomas E Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A Thompson, Robert A Figlin, Norbert Hollaender, Gladys Urbanowitz, William J Berg, Andrea Kay, David Lebwohl, Alain Ravaud, RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 Aug 9;372(9637):449-56..
  2. James C Yao, Manisha H Shah, Tetsuhide Ito, Catherine Lombard Bohas, Edward M Wolin, Eric Van Cutsem, Timothy J Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G E de Vries, Paola Tomassetti, Marianne E Pavel, Sakina Hoosen, Tomas Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 Feb 10;364(6):514-23.
  3. Guy Jerusalem, Richard H de Boer, Sara Hurvitz, Denise A Yardley, Elena Kovalenko, Bent Ejlertsen, Sibel Blau, Mustafa Özgüroglu, László Landherr, Marianne Ewertz, Tetiana Taran, Jenna Fan, Florence Noel-Baron, Anne-Laure Louveau, Howard Burris. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncol 2018 Oct 1;4(10):1367-1374.
  4. Marc I Lorber,Claudio Ponticelli, John Whelchel, Hartmut W Mayer, John Kovarik, Yulan Li, Heinz Schmidli. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005 Apr;19(2):145-52..
  5. Maria Shipkova, Dennis A Hesselink, David W Holt, Eliane M Billaud, Teun van Gelder, Paweł K Kunicki, Mercè Brunet, Klemens Budde, Markus J Barten, Paolo De Simone, Eberhard Wieland, Olga Millán López, Satohiro Masuda, Christoph Seger, Nicolas Picard, Michael Oellerich, Loralie J Langman, Pierre Wallemacq, Raymond G Morris, Carol Thompson, Pierre Marquet. Therapeutic Drug Monitoring of Everolimus: A Consensus Report. 2016 Apr;38(2):143-69.
  6. Alain Ravaud, Shweta R Urva , Kai Grosch, Wing K Cheung, Oezlem Anak, Dalila B Sellami..Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. Eur J Cancer 2014 Feb;50(3):486-95.
  7. John M Kovarik, Doris Beyer, Robert L Schmouder. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos. 2006 Dec;27(9):421-6.
  8. Jennifer A Grabowsky. Drug interactions and the pharmacist: focus on everolimus. Ann Pharmacother. 2013 Jul-Aug;47(7-8):1055-63.
  9. Laura Molenaar-Kuijsten, Dorieke E M Van Balen, Jos H Beijnen, Neeltje Steeghs, Alwin D R Huitema. A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs. Front Pharmacol. 2021 Aug 30;12:670862.
  10. Sabrina Falkowski, Jean-Baptiste Woillard. Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives. Ther Drug Monit. 2019 Oct;41(5):568-574.
  11. W. Cheung , C. Ligia , A. Jappe , O. Anak. Pharmacokinetic (PK) profile of a single dose of everolimus (10 mg) administered with a low- or high-fat meal and under fasting conditions in healthy subjects. Meeting Abstract | 2011 ASCO Annual Meeting I.
  12. Masaki Hirabatake, Tomoyuki Mizuno, Hironori Kato, Tohru Hashida.Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer. Eur J Clin Pharmacol. 2019 Sep;75(9):1309-1318.
  13. J M Kovarik, D Beyer, M N Bizot, Q Jiang, M J Allison, R L Schmouder. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005 Oct;60(4):434-7.
  14. Geoffrey Strobbe, Diane Pannier, Ilyes Sakji, Alexandre Villain, Frédéric Feutry, Guillaume Marliot. Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: A case report. J Oncol Pharm Pract 2020 Oct;26(7):1743-1749.
  15. J M Kovarik, D Beyer, M N Bizot, Q Jiang, M Shenouda, R L Schmouder. Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol 2005 Mar;61(1):35-8.
  16. Andrew R Miesner, Marissa Ausman, Benjamin Dagraedt, Joseph Zieminski. Probable Drug Interaction Between Everolimus and Clarithromycin. Ann Pharmacother 2016 Aug;50(8):689-90.
  17. P N Tran, L C Pinter-Brown. Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin’s lymphoma. J Clin Pharm Ther 2017 Dec;42(6):776-779.
  18. O Mir, V Poinsignon, M Arnedos, S Delaloge, A Paci. Pharmacokinetic interaction involving fenofibrate and everolimus. Ann Oncol 2015 Jan;26(1):248-249.
  19. Remy B. Verheijen, Florence Atrafi, Jan H.M. Schellens, Jos H. Beijnen, Alwin D.R. Huitema, Ron H.J. Mathijssen, Neeltje Steeghs. Pharmacokinetic optimization of everolimus dosing in oncology: a randomized crossover trial. Clin Pharmacokinet, 2018, 57:637-644.